article thumbnail

Dr. Lolettima O. Johnson Celebrated for Dedication to the Field of Medicine

The Pharma Data

Doctor Johnson has had an inspiring career that encompasses several aspects of the pharmacy industry. Doctor Johnson aspires to incorporate the latest technologies available in healthcare to care for her patients. Subsequently, she decided to pursue a higher education in pharmacology following her high school graduation.

article thumbnail

Analysis Life Sciences Thank You FDA’s nonprescription advisors find no efficacy for phenylephrine

Agency IQ

In 2007, an FDA advisory committee weighed phenylephrine’s GRASE status, prompted by a Citizen Petition questioning its effectiveness In December 2007, the FDA’s Nonprescription Drugs Advisory Committee met to discuss the efficacy of phenylephrine 10 mg , the oral dosage approved for OTC use.

Science 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Mifepristone Manufacturer Wins First Round in West Virginia

Drug & Device Law

In 2007 (during the Bush Administration), Congress amended the FDCA to provide for Risk Evaluation and Mitigation Strategy (“REMS”), “to assure safe use,” which the FDA applied to mifepristone. Sorsaia , 2023 WL 3211847, at *2. Its] FDA approval allows it to sell mifepristone nationwide. . . . [T]he T]he growing market for mifepristone. .

article thumbnail

NPP, DCC, And FDA-Regulated Medical Products

Drug & Device Law

They can regulate doctors, pharmacies, and grocery stores, but cannot ban an FDA-approved drug like they can pork that comes from pigs not raised in a specific way, the gist of the California law at issue in NPP. Likewise, states cannot ban a drug that FDA has approved, including ones that once were considered street drugs.

article thumbnail

Beating FDCA-Based Negligence Per Se Claims on Non-Preemption Grounds

Drug & Device Law

Indeed, one of Bexis’ very first blogposts , back in 2007, was a comprehensive review of non-preemption defenses to negligence per se. The very first non-preemption defense to negligence per se mentioned in Bexis’ 2007 post was legislative intent. Bexis’ 2007 post , though dated, is a good place to begin that familiarization.